Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:59:02 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Redeye Initiates Coverage of Sprint Bioscience

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Redeye Initiates Coverage of Sprint Bioscience

2021-10-04 10:05:00

Redeye sees an improved outlook for Sprint Bioscience, as highlighted by its recently announced USD 277m licensing deal for oncology project Vps34. The pipeline of additional candidates for partnering bolsters our conviction. After a period of slow development for its partnered projects, the in our opinion modestly valued company is now in good shape, with its recently completed capital raise providing a solid runway until the next potential milestone payments.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/